Xiao Yu

8.0k total citations · 1 hit paper
57 papers, 3.0k citations indexed

About

Xiao Yu is a scholar working on Molecular Biology, Immunology and Epidemiology. According to data from OpenAlex, Xiao Yu has authored 57 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 27 papers in Immunology and 8 papers in Epidemiology. Recurrent topics in Xiao Yu's work include interferon and immune responses (15 papers), Inflammasome and immune disorders (8 papers) and Autophagy in Disease and Therapy (7 papers). Xiao Yu is often cited by papers focused on interferon and immune responses (15 papers), Inflammasome and immune disorders (8 papers) and Autophagy in Disease and Therapy (7 papers). Xiao Yu collaborates with scholars based in China, United States and Thailand. Xiao Yu's co-authors include Sha Jin, Steven W. Elmore, Christin Tse, Michael J. Mitten, Saul H. Rosenberg, Stephen W. Fesik, Stephen K. Tahir, Alexander R. Shoemaker, Haichao Zhang and Xiufen Yang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Xiao Yu

53 papers receiving 3.0k citations

Hit Papers

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family In... 2008 2026 2014 2020 2008 500 1000 1.5k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiao Yu China 22 1.9k 665 608 298 292 57 3.0k
Yuhua Li China 31 1.3k 0.7× 739 1.1× 757 1.2× 518 1.7× 256 0.9× 148 3.1k
Alessandra Fragale Italy 22 1.6k 0.8× 961 1.4× 632 1.0× 151 0.5× 235 0.8× 34 2.7k
Vasu Punj United States 35 1.9k 1.0× 393 0.6× 786 1.3× 659 2.2× 120 0.4× 79 3.4k
Kenji Yamato Japan 33 1.9k 1.0× 542 0.8× 763 1.3× 328 1.1× 181 0.6× 86 3.1k
Yongchang Qiu United States 20 1.4k 0.7× 874 1.3× 653 1.1× 154 0.5× 94 0.3× 58 3.0k
Laurent Genestier France 31 2.0k 1.0× 1.9k 2.8× 635 1.0× 626 2.1× 431 1.5× 64 4.6k
Roberta Visconti Italy 34 2.1k 1.1× 876 1.3× 1.2k 1.9× 649 2.2× 106 0.4× 73 4.7k
Roberto R. Rosato United States 32 2.3k 1.2× 314 0.5× 665 1.1× 350 1.2× 243 0.8× 61 3.3k
Hamid Kashkar Germany 34 2.5k 1.3× 1.0k 1.5× 614 1.0× 447 1.5× 92 0.3× 73 3.7k
Hua Xiang China 30 1.2k 0.6× 575 0.9× 433 0.7× 355 1.2× 147 0.5× 98 2.6k

Countries citing papers authored by Xiao Yu

Since Specialization
Citations

This map shows the geographic impact of Xiao Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao Yu more than expected).

Fields of papers citing papers by Xiao Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiao Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao Yu. The network helps show where Xiao Yu may publish in the future.

Co-authorship network of co-authors of Xiao Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiao Yu. A scholar is included among the top collaborators of Xiao Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiao Yu. Xiao Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Liying, et al.. (2025). Palmitoylation of TBK1 enhances the type I interferon signaling and strengthens anti-malarial immunity in mice. Nature Communications. 16(1). 10109–10109. 1 indexed citations
2.
Jiang, Huaji, Z. Hu, Jiansen Lu, et al.. (2025). VANGL2 alleviates inflammatory bowel disease by recruiting the ubiquitin ligase MARCH8 to limit NLRP3 inflammasome activation through OPTN-mediated selective autophagy. PLoS Biology. 23(2). e3002961–e3002961. 3 indexed citations
3.
Lu, Jiansen, Zhiqiang Hu, Huaji Jiang, et al.. (2024). Dual nature of type I interferon responses and feedback regulations by SOCS1 dictate malaria mortality. Journal of Advanced Research. 73. 295–310. 1 indexed citations
4.
Li, Hongyu & Xiao Yu. (2023). Natural killer cells: Warriors against malaria. Cell Host & Microbe. 31(4). 576–577. 1 indexed citations
5.
Hu, Z., Jiansen Lu, Huaji Jiang, et al.. (2023). VANGL2 inhibits antiviral IFN-I signaling by targeting TBK1 for autophagic degradation. Science Advances. 9(25). eadg2339–eadg2339. 15 indexed citations
6.
Jiang, Huaji, Jiansen Lu, Hongyu Li, et al.. (2023). Pristimerin suppresses AIM2 inflammasome by modulating AIM2-PYCARD/ASC stability via selective autophagy to alleviate tendinopathy. Autophagy. 20(1). 76–93. 26 indexed citations
7.
Du, Yang, Zhiqiang Hu, Jiansen Lu, et al.. (2022). Activation of cGAS‐STING by Lethal Malaria N67C Dictates Immunity and Mortality through Induction of CD11b+Ly6Chi Proinflammatory Monocytes. Advanced Science. 9(22). e2103701–e2103701. 11 indexed citations
8.
Zhang, Qinqin, Mengnan Zeng, Beibei Zhang, et al.. (2022). Salvianolactone acid A isolated from Salvia miltiorrhiza ameliorates lipopolysaccharide-induced acute lung injury in mice by regulating PPAR-γ. Phytomedicine. 105. 154386–154386. 17 indexed citations
10.
Nie, Qing, Yue Hu, Xiao Yu, Xiao Li, & Xuedong Fang. (2022). Induction and application of ferroptosis in cancer therapy. Cancer Cell International. 22(1). 12–12. 98 indexed citations
11.
Phillips, Darren C., Fritz G. Buchanan, Dong Cheng, et al.. (2021). Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors. Cancer Research. 81(12). 3402–3414. 32 indexed citations
13.
Jin, Sha, Dan Cojocari, Julie J. Purkal, et al.. (2020). 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Clinical Cancer Research. 26(13). 3371–3383. 126 indexed citations
14.
Guo, Jun, Xiao Yu, Xin Lü, et al.. (2019). Empowering therapeutic antibodies with IFN-α for cancer immunotherapy. PLoS ONE. 14(8). e0219829–e0219829. 20 indexed citations
15.
Dong, Guofeng, Xiao Yu, Xiaoxiao Zhang, et al.. (2017). Antimicrobial and anti-biofilm activity of tannic acid against Staphylococcus aureus. Natural Product Research. 32(18). 2225–2228. 165 indexed citations
16.
Tahir, Stephen K., Morey L. Smith, Larry R. Solomon, et al.. (2017). Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors. Blood. 130. 2812–2812. 8 indexed citations
17.
Tan, Peng, Lian He, Jun Cui, et al.. (2017). Assembly of the WHIP-TRIM14-PPP6C Mitochondrial Complex Promotes RIG-I-Mediated Antiviral Signaling. Molecular Cell. 68(2). 293–307.e5. 61 indexed citations
18.
Yu, Xiao, Mingjun Wang, Peng Tan, et al.. (2016). Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality. Immunity. 45(5). 1093–1107. 96 indexed citations
19.
Tse, Christin, Alexander R. Shoemaker, Jessica Adickes, et al.. (2008). ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Cancer Research. 68(9). 3421–3428. 1513 indexed citations breakdown →
20.
Ackler, Scott, Xiao Yu, Michael J. Mitten, et al.. (2008). ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 7(10). 3265–3274. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026